A phase III, multicenter, open-label, randomised study to evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (B-Pd) versus pomalidomide plus bortezomib and dexamethasone (PVd) in participants with relapsed/refractory multiple myeloma [207499] [DREAMM 8]